

**Title:**

**Authors:**

**Affiliations**

**Contact:**

1. Email
2. Mobile Phone

**Introduction**:

DELETE THIS GUIDELINE PARAGRAPH. DESCRIBE THE ISSUE AT HAND IN ONE OR TWO PARAGRAPHS AND HOW THE STUDY WOULD IMPACT IMPROVING THE PRESENTED ISSUE. EXAMPLE: "THE LITERATURE DESCRIBES A 10% BICUSPID DISEASE PREVALENCE IN TAVI CANDIDATES; HOWEVER, OUR CENTER HAS REPORTED A HIGHER PREVALENCE. OUR PLAN IS TO CONDUCT A REGIONAL/NATIONAL MULTICENTER STUDY TO EVALUATE THE TRUE PREVALENCE IN OUR REGION."

**Objective:**

DELETE THIS GUIDELINE PARAGRAPH. IN ONE SENTENCE, DESCRIBE THE OBJECTIVE OF THIS STUDY. FOR EXAMPLE: "TO DESCRIBE THE PREVALENCE OF BICUSPID VALVE DISEASE IN COLOMBIA."

**Methods:**

DELETE THIS GUIDELINE PARAGRAPH. DESCRIBE THE POPULATION TO BE INCLUDED IN THE STUDY (E.G., "PATIENTS UNDERGOING TAVI IN 10 COLOMBIAN CENTERS"), WITH INCLUSION CRITERIA (E.G., PATIENTS WITH SEVERE AORTIC STENOSIS) AND EXCLUSION CRITERIA (SEVERE AORTIC REGURGITATION, ENDOCARDITIS, RHEUMATIC FEVER, ETC.). DESCRIBE THE METHODS IN GENERAL TERMS: STUDY PERIOD, LOCATIONS, WHO WILL COLLECT THE DATA AND WHERE, ETHICAL CONSIDERATIONS (WHETHER CONSENT IS REQUIRED AND HOW ETHICAL APPROVAL WILL BE PROCESSED), AND IN GENERAL TERMS, HOW RESULTS WILL BE PRESENTED.

THE METHODS SECTION MUST NOT EXCEED THE THIRD PAGE; THE FOURTH PAGE SHOULD BE FOR REFERENCES ONLY. THE CONTENT OF THIS SECTION AIMS TO ENABLE EVALUATORS TO DETERMINE IF THE STUDY IS FEASIBLE AND WHETHER ITS RESULTS WILL CONTRIBUTE TO IMPROVED KNOWLEDGE.

**Reference:**